Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug 20;44(4):368-369.
doi: 10.47626/1516-4446-2022-2503.

Anti-amyloid agents for treating incipient Alzheimer's disease: a new hope?

Julia C Loureiro  1 , Luiz Fernando A L Silva  1 , Marcos V Pais  1 , Orestes V Forlenza  1
Affiliations
Editorial

Anti-amyloid agents for treating incipient Alzheimer's disease: a new hope?

Julia C Loureiro et al. Braz J Psychiatry. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

References

    1. Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development pipeline: 2021. Alzheimers Dement (NY) 2021;7:e12179. - PMC - PubMed
    1. van Dyck CH. Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: pitfalls and promise. Biol Psychiatry. 2018;83:311–9. - PMC - PubMed
    1. Penninkilampi R, Brothers HM, Eslick GD. Safety and efficacy of anti-amyloid-β immunotherapy in Alzheimer’s disease: a systematic review and meta-analysis. J Neuroimmune Pharmacol. 2017;12:194–203. - PubMed
    1. Sperling RA, Jack CR, Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367–85. - PMC - PubMed
    1. Kuller LH, Lopez OL. ENGAGE and EMERGE: truth and consequences? Alzheimers Dement. 2021;17:692–5. - PMC - PubMed

Publication types

Substances